Founders Message: May 2, 2022

To Our Valued Shareholders, Supporters, Friends and Colleagues:

Big things are happening at Optimi. Thank you for being a part of them.

As we’ve kicked off our year of commercialization, we’ve experienced an incredible response from backers at every level. The knowledge that so many of you are excited to be investing in the scalable future of natural, accessible psilocybin and its implications for mental health is a powerful affirmation of everything we stand for.

On the ground, watching our facility take shape and seeing our first crop of GMP psilocybin grow, we’re conscious both of all that we’ve achieved so far and of how much we still have to accomplish.

Being a top tier ingredient supplier of pharmaceutical grade psilocybin and functional mushrooms is our number one goal. This is precisely why we have invested so heavily in our 10,000 square foot GMP-grade facility.

It’s simple: to be the best, we have to set the highest operational standards in the industry, bar none.

Why is growing natural, pharmaceutical grade psilocybin so important to our business and customers seeking our products?

First, as a company we believe that the only pathway to a regulated safe supply of psilocybin in Canada must come from a licensed, GMP facility. In fact, we were pleased to hear Health Canada make that important distinction in an industry meeting on March 24, 2022 when they were asked about quality of production and supply.

Second, properly sourced, pharmaceutical grade psilocybin is the only way to know for sure that you’re giving your body the highest, purest, and most bioavailable form of an ingredient possible. Our psilocybin and functional mushrooms are analyzed in our state-of-the-art laboratory and sent for third party analytical testing to ensure an extremely high standard of purity and maximum absorption.

And third, companies in emergent industries that take the time to get it right like Optimi has are rare. We believe this shows our commitment to safety, transparency and efficacy, which is why we are excited to announce that we’ll be opening the doors of our Princeton, British Columbia facility to the world on Friday, May 27th, 2022.

We’d like to invite all of you to join us. To RSVP, please email event organizer Michael Kydd at

And that’s not all…

We know that success is impossible without community, so we’ll be welcoming the entire town of Princeton and residents from the surrounding area for this unique celebration.

This sector has the power to touch people’s lives not just as medicine, but as a natural and sustainable industry that can drive job creation for the Main Streets of North America. We’re proud of Princeton and tremendously grateful for the support we’ve received from this wonderful town. Now we’re eager to pay it forward.

Thank you.

JJ, Dane, Bryan, and Jacob




Investor Relations
Phone: +1 (902) 880 6121


Optimi Health Corp. is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP grade psilocybin and synthetic psychedelic substances, as well as functional mushrooms that focus on the health and wellness markets. Built with the purpose of producing scalable psychedelic formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe drug products throughout the world. Optimi’s products are grown at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia, making it the largest psilocybin and MDMA cultivator in North America.


Investor Relations
Phone: +1 (902) 880 6121


This news release contains forward‐looking statements and forward‐looking information within the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward‐looking statements and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ materially from those expressed in such forward‐looking statements. No assurance can be given that these expectations will prove to be correct and such forward‐looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release. In particular and without limitation, this news release contains forward‐ looking statements pertaining to activities proposed to be conducted under the Company’s dealer’s license and associated business related to Psilocybin and Psilocin and Optimi’s plans, focus and objectives.

Forward‐looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward‐looking statements. Such risks and uncertainties include, but are not limited to, the impact and progression of the COVID‐19 pandemic and other factors set forth under “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual information Form dated January 12, 2022, and other continuous disclosure filings available under Optimi’s profile at Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward‐looking statement.

Any forward‐looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Products do not contain psilocybin

Get news & updates directly to your inbox.
Thank you for your interest in our investor presentation.

Please sign up here and we will send the presentation to your inbox.
Interested In Optimi? Let's Talk.